As Navitus Health Solutions celebrates its twenty-year legacy and looks ahead to the future, an area of focus is workplace culture. Our people are...

This summer, Navitus celebrated its 20^th anniversary as an organization. In honor of that, we sat down with David Fields to reflect on the company's...

2023 is a year of celebration at Navitus. Not only is it the 20th anniversary of our founding, but 2023 also marks 10 years of Navitus' residency...

Our recent August Pharmacy and Therapeutics (P&T) Committee meeting reviewed the release of various Humira® biosimilars. Staying true to our...

In an ever-changing legislative landscape, we want to help our clients and partners stay informed of the latest happenings and how proposed policies...

This summer has seen a continuation of the long-awaited market entry of Humira^® (adalimumab) biosimilars. As of July 1, nine additional biosimilars...

We are pleased to share our 2022 Drug Trend Report with you. This year's report highlights our success in managing pharmacy benefit costs for our...

We had the pleasure of connecting with our new Chief Financial Officer, George Hepburn, to discuss what excites him about his new role, what inspires...

We recently sat down with Ken Goodnight to discuss his key priorities as Chief Transformation & Digital Officer and to learn about his professional...

The market entry of biosimilars to Humira^® (adalimumab) is long-awaited. These products have the potential to improve affordability in the near- and...

As we enter 2023, David Fields is sharing his top forecasts and takeaways for plan sponsors and the PBM industry.

As we continue our employee spotlight series, we are excited to highlight Shelly McAdoo, Navitus’ new Diversity, Equity and Inclusion (DEI) Senior...